Stephnie A. John

California's Health Care Transactions Review Law: Regulatory Revisions Effective Immediately

The Consequences And Costs Of Redesigning The Part D Program

Opposition To The Use Of March-In Rights To Lower Drug Prices

Learning From Experience: Medicare Drug Price Negotiation Program Updates

A Mintz Health Care Roundtable: Current Trends In State Health Care Transaction Review And What To Expect In 2024

Mintz IRA Update — Biden Administration Proposes Allowing Agencies To 'March-In' To Control Rising Drug Prices

Mintz IRA Update — The IRA In 2024: The Medicare Drug Price Negotiation Program In Full Swing And Other Developments

Telehealth Update: DEA Extends Flexibility In Prescribing Controlled Substances Via Telehealth Through 2024

Transforming Primary Care: CMS Launches Making Care Primary (MCP) Model

The Supreme Court's SuperValu Decision On The "Knowingly" Element In The False Claims Act: Protecting Against Liability When There Is Regulatory Ambiguity